Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 6/20 | 0.52 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.51 |
| ▸ | RORC | P51449 | 2/20 | 0.46 |
| ▸ | SYK | P43405 | 3/20 | 0.45 |
| ▸ | CFTR | P13569 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.43 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.43 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3417227 | 0.89 | CNR1 (0.46) | EGFRNOX4RORCSYKCNR1 | |
| SCHEMBL608498 | 0.86 | KDM4C (0.53) | EGFRNOX4RORCSYKMAPT | |
| SCHEMBL12863172 | 0.86 | EGFR (0.55) | EGFRNOX4SYKMAPTCA12 | |
| SCHEMBL4116154 | 0.85 | KDM4C (0.52) | EGFRNOX4RORCSYKMAPT | |
| Potassium Ion SCHEMBL4116152 | 0.84 | RORC (0.47) | RORCSYKCA12CA1CA2 | |
| SCHEMBL11937520 | 0.84 | KDM4E (0.43) | EGFRRORCCFTRCNR1FFAR1 | |
| SCHEMBL11937518 | 0.82 | NLRP3 (0.59) | RORCMAPTP2RX4 | |
| Sulfuric Acid SCHEMBL1170031 | 0.82 | PPARA (0.49) | EGFRNOX4RORCSYKMAPT | |
| SCHEMBL12877595 | 0.81 | EGFR (0.55) | EGFRRORCSYKMAPTCNR1 | |
| SCHEMBL26181060 | 0.80 | RORC (0.45) | EGFRRORCCFTRCA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2215050-B1 | MANUFACTURING METHOD OF 2-HYDROXY-5-PHENYLALKYLAMINOBENZOIC ACID DERIVATIVES AND THEIR SALTS | NEUROTECH PHARMACEUTICALS CO LTD (KR) | 2012-06-27 | — | — | EP | claimed |
| US-20110028757-A1 | MANUFACTURING METHOD OF 2-HYDROXY-5-PHENYLALKYLAMINOBENZOIC ACID DERIVATIVES AND THEIR SALTS | NEUROTECH PHARMACEUTICALS CO., LTD. (KR) | 2011-02-03 | — | — | US | claimed |
| EP-2215050-A2 | MANUFACTURING METHOD OF 2-HYDROXY-5-PHENYLALKYLAMINOBENZOIC ACID DERIVATIVES AND THEIR SALTS | Neurotech Pharmaceuticals Co., Ltd. (KR) | 2010-08-11 | — | — | EP | claimed |
| WO-2009064084-A2 | MANUFACTURING METHOD OF 2-HYDROXY-5-PHENYLALKYLAMINOBENZOIC ACID DERIVATIVES AND THEIR SALTS | NEUROTECH CO., LTD. (KR) | 2009-05-22 | — | — | WO | claimed |
| EP-4261201-A1 | METHOD FOR PREPARING 2-HYDROXY-5-[2-(4-(TRIFLUOROMETHYLPHENYL)ETHYLAMINO)]BENZOIC ACID | GNT Pharma Co., Ltd (KR) | 2023-10-18 | — | — | EP | disclosed |
| WO-2022121853-A1 | METHOD FOR PREPARING 2-HYDROXY-5-[2-(4-(TRIFLUOROMETHYLPHENYL)ETHYLAMINO)]BENZOIC ACID | 吉恩特药业株式会社 | 2022-06-16 | — | — | WO | disclosed |
| EP-2215050-B1 | MANUFACTURING METHOD OF 2-HYDROXY-5-PHENYLALKYLAMINOBENZOIC ACID DERIVATIVES AND THEIR SALTS | NEUROTECH PHARMACEUTICALS CO LTD (KR) | 2012-06-27 | — | — | EP | disclosed |
| US-20110028757-A1 | MANUFACTURING METHOD OF 2-HYDROXY-5-PHENYLALKYLAMINOBENZOIC ACID DERIVATIVES AND THEIR SALTS | NEUROTECH PHARMACEUTICALS CO., LTD. (KR) | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028757-A1 | MANUFACTURING METHOD OF 2-HYDROXY-5-PHENYLALKYLAMINOBENZOIC ACID DERIVATIVES AND THEIR SALTS | PAH, HACL2, HAAO | EGFR 1211/4885NOX4 3427/4885RORC 4505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.